EIKN Eikon Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-31
Why EIKN matters now
Eikon Therapeutics, Inc. Common Stock (EIKN) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.21 with -4.26% on the session and $498.6M in market capitalization; recent performance reads 1-month -9.68% and YTD -35.93%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-83.0M, and EPS of $-1.53. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -464.9%.
The latest indexable market news headline is "Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.94
P/S
0.00
EV/EBITDA
-0.80
DCF Value
$-2.83
FCF Yield
-464.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
43.1%
ROA
-19.1%
ROIC
-20.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-83.0M | $-1.53 |
| Q4 2025 | $0.00 | $-79.7M | $-1.47 |
| FY 2025 | $0.00 | $-324.2M | $-6.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.26
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.